Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bang, Soo-Mee | - |
dc.contributor.author | Kang, Jin-Hyoung | - |
dc.contributor.author | Hong, Min Hee | - |
dc.contributor.author | Ahn, Jin-Seok | - |
dc.contributor.author | Oh, So Yeon | - |
dc.contributor.author | Baek, Jin Ho | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Shin, Seong Hoon | - |
dc.contributor.author | Kim, Young-Joo | - |
dc.contributor.author | Gil, Ha-Yeong | - |
dc.contributor.author | Park, Hyung-Eun | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Park, Eun-Lyeong | - |
dc.date.accessioned | 2021-08-30T04:02:07Z | - |
dc.date.available | 2021-08-30T04:02:07Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2021-01-18 | - |
dc.identifier.issn | 1076-0296 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/50088 | - |
dc.description.abstract | This study assessed epidemiologic data and clinical outcomes, including venous thromboembolism (VTE) recurrence and bleeding events, in patients with cancer-associated VTE, and assessed factors associated with clinical outcomes. Data were extracted from retrospective medical-chart review of adult patients diagnosed with cancer-associated deep vein thrombosis or pulmonary embolism who received anticoagulation treatment for >= 3 months. Patients were classified by: low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), and other anticoagulants. First VTE recurrence and bleeding events, and factors associated with their occurrence, were assessed during the initial 6 months of treatment. Overall, 623 patients (age: 63.7 +/- 11.3 years, 49.3% male) were included (119, 132, and 372 patients in LMWH, DOACs and other anticoagulants groups, respectively). The cumulative 6-month incidence of VTE recurrence was 16.6% (total), 8.3% (LMWH), 16.7% (DOACs), and 20.7% (other); respective bleeding events were 22.5%, 11.0%, 12.3%, and 30.7%). VTE recurrence and bleeding rates differed only between LMWH and other anticoagulants (HR 2.4, 95% CI: 1.2-5.0 and 3.6, 1.9-6.8, respectively). These results highlight the importance of initial VTE treatment choice for preventing VTE recurrence and bleeding events. LMWH or DOACs for >= 3 months can be considered for effective VTE management in cancer patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS INC | - |
dc.title | Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.identifier.doi | 10.1177/1076029620979575 | - |
dc.identifier.scopusid | 2-s2.0-85099905668 | - |
dc.identifier.wosid | 000612853400001 | - |
dc.identifier.bibliographicCitation | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, v.27 | - |
dc.relation.isPartOf | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | - |
dc.citation.title | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | - |
dc.citation.volume | 27 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | venous thromboembolism | - |
dc.subject.keywordAuthor | low-molecular-weight heparin | - |
dc.subject.keywordAuthor | direct oral anticoagulants | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.